This series of BIA Brexit Briefings will provide monthly updates for our UK and International audiences answering 'What does Brexit mean for Biotechnology in the UK and beyond?'
Following the outcome of the UK’s referendum on membership of the European Union, the BIA has worked closely with members and stakeholders to identify the threats and opportunities for biotech post-Brexit and to represent the sector.
Our BIA Brexit Briefing webinars provide a monthly update on Government policy, progress of working groups, and how these potentially affect companies in life sciences.
We will continue to cover the main ongoing issues, but we will also provide an update after the Jeremy Hunt/Greg Clark letter on medicines regulation and the BIA/MHRA conference speech by Lord O’Shaughnessy.
BIA 2017 Supporters